Kornimate/medical-research-clean huggingface dataset:
lhc-cidi-5 in hong kong

Conditions: Major Depressive Episode (MDE); Major Depressive Disorder (MDD); Persistent Depressive Disorder (PDD); Suicidal Ideation; Suicidal Plan; Suicidal Attempt; Suicidal Gesture; Nonsuicidal Self-Injury; Manic Episode; Hypomanic; Bipolar I Disorder; Bipolar Sub Disorder; Bipolar II Disorder; Generalized Anxiety Disorder (GAD); Intermittent Explosive Disorder (IED); Panic Attack; Panic Disorder; Obsessive-Compulsive Disorder (OCD); Posttraumatic Stress Disorder (PTSD); PCL-SC PTSD; PCL-5 PTSD; Alcohol Use Disorder (AUD); Substance Use Disorder (SUD)

Summary: the world health organization composite international diagnostic interview-5th (cidi-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the diagnostic and statistical manual of mental disorders 5th edition (dsm-5) and international classification of diseases 10th edition (icd-10). however, retrospective measurements like the cidi-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders. to mitigate this issue, the life history calendar (lhc) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the cidi-5 to measure the lifetime prevalence of mental disorders. the lhc is a grid structure with columns representing time units and rows representing life domains under study. in a study conducted in nepal, combining the cidi-5 with the lhc resulted in a significant increase in the detection of mental disorders compared to using the cidi-5 alone. this approach did not lead to an increase in false positives after clinical validation. this experiment aims to adapt a hong kong version of the lhc based on the nepalese model and evaluate the effectiveness of the lhc-assisted cidi-5 (lhc-cidi-5) compared to the cidi-5 alone in assessing mental disorders.


Eligibility criteria:
inclusion criteria: * all household members aged 25 years old and over are randomly sampled from the census and statistics department list of quarters * live in the address sampled from the census and statistics department list of quarters * reside in hong kong for at least six months in the past year * able to read and communicate in chinese or english * without linguistic or cognitive difficulties exclusion criteria: * domestic workers

Keywords: life history calendar cidi recall bias retrospective reporting lifetime prevalence mental disorders
lucentis as an adjuvant therapy with ttt-icg based in choroidal melanoma

Conditions: Choroidal Melanoma

Summary: to report preliminary results on safety and tolerability of intravitreal injection of ranibizumab (lucentis) combined with transpupillary thermotherapy (ttt)+ indocyanine green (icg)-based photodynamic therapy (pdt) in the treatment of choroidal melanoma.


Eligibility criteria:
inclusion criteria: * age \> 18 yo. * primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in the largest vessel diameter and 6 mm or less in the apical height. * location of the tumor posterior to the equator. * documented growth by a/b scan. * risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at the optic disc) * ability to provide inform consent. * comply with the study assessment for the cooperation of the study. exclusion criteria: * pregnancy or lactation. * premenopausal women not using adequate contraception; surgical sterilization or use of oral contraception, barrier contraception with either a condom or diaphragm or in conjunction with spermicidal gel, an iud or contraceptive hormon implant or patch. * current infection or inflammation in either eye. * extension of tumor into the orbit. * retinal spread or metastatic disease. * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * any known allergy to any of the components to be used in the study. * participation in another simultaneous medical investigation or trial.

Keywords: choroidal melanoma lucentis ttt-icg
a strength-based employment maintenance program for individuals on the autism spectrum

Conditions: Autism

Summary: the investigators are looking to evaluate how effective a training program that focuses on character strengths may be in improving job maintenance skills in young adults. the investigators are examining the effects of this intervention in young adults who feel they would like to help in improving their satisfaction with work, and in keeping their jobs.

individuals with autism possess employable and valuable strengths and abilities. unfortunately, despite these strengths, individuals with autism experience challenges in obtaining and maintaining employment. traditionally, the majority of interventions designed for autism (including those focused on employment) focus on remediating deficits, without harnessing the strengths of those with autism. this deficit-based approach (i.e. to fix what is deficient in a person with autism) has triggered increasing criticism and dissatisfaction from the autism community. a growing shift toward strength-based training tools represent a holistic approach to treatment of autistic individuals by acknowledging and using their strengths to improve outcomes. to date, no strength-based employment programs have been examined in individuals with autism. thus, in the current project, the investigators aim to develop and test a strength-based employment program. at kessler foundation, the investigators have developed a strength-based training tool: kessler foundation strength identification and expression (kf-stride®) which targets job interview skills by teaching individuals with autism to identify and express their personal strengths to a future employer. in the current proposal, the investigators aim to adapt this program to specifically target job maintenance skills.

Eligibility criteria:
inclusion criteria: * lives in the united states of america * between the ages of 14-26 * speaks english well and at a 4th grade reading level exclusion criteria: * had a stroke, traumatic brain injury, or neurological injury or disease in the past(like brain tumor or epilepsy) * has a history of significant psychiatric illness(like schizophrenia or psychosis) * has uncontrolled seizures or other unstable medical complications

Keywords: autism, autism spectrum disorder, asd
correlation of artherosclerotic plaque volume and intima media thickness with soluble p-selectin

Conditions: Cardiovascular Risk Factors; Coronary Artery Disease; Cerebrovascular Disease; Peripheral Artery Disease

Summary: the proposed project is a prospective observational, single-center cohort study aimed to examine the progression of atherosclerotic alterations of the carotid arteries (imt, plaque volume) during a follow-up of up to four years and to correlate the observed changes with traditional and novel biomarkers of atherosclerosis. a total of 600 subsequent patients with or established cardiovascular disease or at least one cardiovascular risk will be tested with a high-frequency ultrasound probe equipped with automated imt measurements and 3d quantitative plaque volumetry. plasma samples will be collected and tested for traditional and novel cardiovascular risk factors. both ultrasound examinations and blood sampling will be repeated once per year to assess changes in these parameters over time depending on treatment modalities, which are left to the discretion of the treating physicians. the primary endpoint of the planned study will be the correlation between p-selectin and the progression of atherosclerosis as measured by plaque volume and imt in the carotid and femoral arteries, respectively. secondary endpoints will include the correlation of established (hypertension, smoking, diabetes, dyslipidemia) and novel risk factors (hscrp, p-selectin, cholesteryl ester transfer protein (cetp), intercellular adhesion molecule-1 (icam-1), cetp taqib polymorphism) with the progression of atherosclerosis, the correlation of cardiovascular events with the progression of atherosclerosis and the additional predictive value of plaque volume and imt compared to an established risk score (score card).


Eligibility criteria:
inclusion criteria: * patients (male and female) aged 30 to 85 years * with at least one traditional cardiovascular risk factor (hypertension, smoking, diabetes, dyslipidemia, family history) or established coronary artery disease, cerebrovascular disease, or peripheral artery disease diagnosed by objective testing exclusion criteria: * lack of informed consent * the impossibility of follow-up testing once per year for the following four years
a community health worker-led program for chronic pain and loneliness in older adults

Conditions: Chronic Pain

Summary: the goal of this clinical trial is to test a new community health worker-delivered program (strengthening connections to overcome pain, or scoop) that teaches strategies for managing chronic pain and loneliness to older adults living in rural areas. the main questions it aims to answer are: 1. does participating in scoop result in less pain interference with daily life? 2. does participating in scoop result in decreased loneliness? 3. what is the level of participant engagement in scoop? researchers will compare people who have participated in scoop with people who have not participated in scoop to see if scoop is helpful in decreasing pain interference and loneliness. participants will: 1. watch brief videos teaching strategies to manage pain and boost social connections. 2. engage in up to 7 weekly coaching sessions with a community health worker. 3. complete two telephone interviews about health, mental health, and functioning: one at baseline, and one 2 months later.


Eligibility criteria:
inclusion criteria: * age \>= 60 years; * have a mobile or landline phone; * self-reported chronic musculoskeletal pain (pain in muscles or joints for \>= 3 months, \>=4 (0-10 scale) average pain level over last week, \>=1 day/previous 30 when pain made it difficult to do usual activities); * self-reported loneliness (feeling lonely "some of the time" or more often); * able to converse comfortably in english. exclusion criteria: * serious acute illness or hospitalization in the last month; * planned major surgery in the next three months that would interfere with program participation (e.g., knee or hip replacement); * severe cognitive impairment or other severe physical or psychiatric disorder judged by study team to pose a significant barrier to participation.
motivating campus change study

Conditions: Drinking Behavior

Summary: the study evaluates the relative merit of a multi-component pfi presented in the traditional simultaneous delivery (i.e., all components at once) versus a sequential format, wherein individual pfi components are delivered one at a time over several weeks to minimize time and attention demands for each component.

this study builds upon the latest alcohol intervention literature to develop and test the next wave of personalized feedback interventions (pfis) to address harmful alcohol use among college students. the purpose of this research is to determine optimal configuration of pfis to take advantage of the clarity and initial impact of single-component pfis and greater effect size and duration of personalized multi-component pfis. the investigators seek to increase and evaluate engagement with the pfi and text-message materials and boost innovation of both content and process of the intervention. in addition to pfi content and delivery, the investigators will use qualitative and quantitative methods to determine personal relevance of the chosen high-risk events among a sample of students who engage in heavy episodic drinking to better understand duration of pfi effects impacted by fluctuations in drinking associated with high-risk events. prior interventions have targeted drinking in general or a single high-risk drinking event (e.g., spring break), but have not targeted both general and event-specific drinking together. these enhanced intervention effects, could have a significant impact on risks associated with college student drinking, and can be rapidly disseminated and implemented on campuses nationwide to address the public health problem posed by heavy episodic drinking among college students.

Eligibility criteria:
inclusion criteria: * at least 1 heavy episodic drinking episode in the past month * at least 3 negative alcohol related consequences on rutgers alcohol problem index/ young adult alcohol problems screening test in the past 3 months for cohort 1 * at least 2 negative alcohol related consequences on rutgers alcohol problem index/ young adult alcohol problems screening test in the past month for cohort 2 - 5 * indicate they own a cell phone with text message capabilities and consent to receiving text messages exclusion criteria: * doesn't meet inclusion criteria * unwillingness to participate * failure to provide consent * plan to travel internationally in the next 12 months (for intervention text purposes)
a phase ib study of yy-20394 in patients with relapsed or refractory peripheral t-cell lymphoma

Conditions: Relapsed or Refractory Peripheral T-Cell Lymphoma

Summary: a single-arm, open, multicenter study to investigate the efficacy and safety of yy-20394, an oral small molecular inhibitor of pi3k-delta, in patients with relapsed or refractory peripheral t cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. males and/or females over age 18 2. histologically or cytologically confirmed diagnosis of relapsed or refractory peripheral t cell lymphoma. 3. eastern cooperative oncology group performance status of 0 to 2. 4. life expectancy of at least 3 months. 5. at least one measurable lesion according to irwg. 6. adequate organ function. 7. had anti-tumor treatments greater than or equal to 2 weeks prior to the first dose of investigational product (including tki, chemotherapy, radiotherapy, immunotherapy and major surgery). 8. men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose. 9. volunteers did not participate in other clinical trials within 1 month prior to study entry. 10. able to comply with the protocol judged by investigator. 11. provision of signed and dated, written informed consent prior to any study- specific evaluation. exclusion criteria: 1. previous treatment with any pi3k-delta ihinibitors. 2. uncontrolled pleural effusion and ascites. 3. the dosage of steroid hormone ( prednisone equivalent ) was greater than 20mg/day, and lasted for more than 14 days. 4. medical conditions in swallowing, malabsorption, or other chronic gastrointestinal disease that may hamper compliance and/or absorption of the investigational agent. 5. during the study period, drugs that may prolong the qt (such as anti arrhythmic drugs) could not be interrupted. 6. evidence of central nervous system involvement of the malignancy, including invasion of brain parenchyma and meninges, or spinal cord compression. 7. active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy(such as pneumonia). 8. active infection with hepatitis b and c virus ( volunteers with hbsag or hbcab positive and hbv-dna greater than or equal to 1000 corpies/ml or 200iu/ml; hcv antibody and hcv-rna positive ). 9. history of immune deficiency ( acquired or congenital ), or history of organ transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation. 10. presence of severe or uncontrolled cardiovascular disease. 11. the baseline pregnancy test was positive in pregnant women, lactating women or fertile women. 12. according to the judgement of the investigator, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study (such as severe hypertension, diabetes, thyroid diseases, etc.). 13. medical history of other primary malignant tumors in the past 5 years except for the following: clinically cured cervical in situ, local basal cell carcinoma of the skin. -
effect of posture and passive cycling on cardiac autonomic control system in children with severe cerebral palsy

Conditions: Cerebral Palsy

Summary: the investigators will examine the immediate contribution of position and movement on the functioning of the autonomic cardiac control system.

standing position is a routine therapeutic tool for improving bone density in children with cerebral palsy. the autonomous immediate response for these children is defective. in recent years it has been shown that there is an association between bone density and autonomic function . in this paper the investigators will examine how the addition of movement to standing subjects contribute to changes in heart rate and blood pressure. the hypothesis is that the integration of movement while standing presents a change in the autonomic response and thus may improve bone density.

Eligibility criteria:
inclusion criteria: * motor ability of gmfcs iv-v exclusion criteria: * children with hip subluxation * on baclofen inhaler treatment * heart disease * surgical procedures

Keywords: cerebral palsy passive cycling autonomic control system
obesity and mortality

Conditions: Obesity and Overweight

Summary: previous analyses of the national health and nutrition examination survey have suggested that the mortality rate associated with obesity has decreased over calendar time in the u.s. population, potentially due to improvements in the medical care of obesity and its associated diseases. the primary aim of this project is to evaluate whether this reduction in the detrimental association of obesity with mortality rate over calendar time is supported by other data from u.s. prospective studies.


Eligibility criteria:
inclusion criteria: * u.s. based studies with at least 1500 subjects * at least 5 years of mortality follow-up * bmi measured or self-reported available at 2 or more separate calendar time * subjects varied in age at baseline exclusion criteria: * any study that does not meet the inclusion criteria was excluded
a study to evaluate raf265, an oral drug administered to subjects with locally advanced or metastatic melanoma

Conditions: Metastatic Melanoma

Summary: the purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of raf265 in patients with locally advanced and metastatic melanoma. phase ii portion of study (dose expansion) has been cancelled with amendment 7 as of dec 2011.

the ras/raf/mek/erk pathway plays a prominent role in controlling several key cellular functions including growth, proliferation and survival. b-raf is a member of the ras/raf/mek/erk pathway and is frequently mutated in melanoma resulting in activation of the mapk pathway. raf265 is a novel, orally active, small molecule with potent inhibitory activity against b-raf kinase and additional antiangiogenic activity through inhibition of vascular endothelial growth factor receptor type 2 (vegfr-2) in non-clinical studies. the primary objectives of this study are to determine the maximum tolerated dose (mtd), dose limiting toxicities (dlts), and the safety profile of raf265 when administered orally to subjects with locally advanced or metastatic melanoma; to determine the plasma pharmacokinetics (pks) of orally administered raf265; and to evaluate potential pharmacodynamic effects of raf265 using tumor biopsies, peripheral blood samples, and tumor imaging.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of melanoma, locally advanced ajcc stage iiib to metastatic stage iv 2. measurable disease - at least one lesion measured in at least one dimension as ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral computed tomography (ct) scan 3. ecog performance status of 0 or 1 4. no concurrent anticancer or investigational therapy for at least 4 weeks prior to enrollment 5. no major surgery for at least 4 weeks prior to enrollment exclusion criteria: 1. significant cardiac disease or other significant medical/psychiatric disease 2. history of primary central nervous system tumor or brain metastases 3. history of melena, hematemesis, or hemoptysis within the last 3 months 4. previous therapy with certain molecularly targeted agents

Keywords: anti-angiogenesis therapy kinase inhibitor therapy raf inhibitor locally advanced melanoma
variable rate phenylephrine infusion for prevention of spinal-induced hypotension for cesarean delivery

Conditions: Anesthetic Complication Spinal

Summary: rapid administration of crystalloid immediately after induction of spinal anesthesia (coload) to be more effective in terms of managing hypotension as compared to administering crystalloid before spinal anesthesia (preload). phenylehrine infusion is a safe and effective way to reduce incidence and frequency of hypotension during sa for cesarean delivery. hypotension was virtually eliminated by use of high-dose prophylactic phenylephrine infusion at a rate of 100 µg/min and rapid crystalloid coload up to two liters (administration at the time of sa). however, incidence of reactive hypertension was frequent up to 47% with decrease in maternal heart rate (hr). this may raise concern in patients in whom increase of blood pressure may be detrimental, like chronic hypertension and in the presence of a compromised uteroplacental blood flow. a recent study found that infusing phenylephrine at a fixed rate of 75 and 100 ug/min is associated with more episodes of hypertension than placebo or the lower infusion rates of 25 and 50 ug/min respectively. however, there was no reduction in the number of physician interventions (phenylephrine boluses and stopping the infusion) needed to maintain maternal systolic blood pressure within 20% of baseline among all groups. prophylactic fixed rate infusions may have limited application in clinical practice, and a variable rate (i.e. modifying the rate according to hemodynamics) has been advocated. the bolus administration of phenylephrine to treat hypotension is still commonly used, but requests multiple interventions from the anesthesiologists and is time consuming. eighty patients scheduled for cesarean delivery under spinal anesthesia will be assigned to one of two groups. immediately after spinal injection, rapid crystalloid colaod of lactated ringer of 15 ml/kg over a period of 10-15 min will be initiated. patients in group i will receive infusion of normal saline (placebo) and patients in group ii variable infusion rate of phenylephrine started at 0.75 ug/kg (close to the dose of 50 ug/min recommended for fixed infusion rate). the number of interventions needed to maintain maternal systolic blood pressure within 20% of baseline, hemodynamic performance, intraoperative nausea and vomiting, and umbilical cord blood gases will be compared between the two groups. we will define a reliable and safe method to ensure maternal hemodynamic stability during spinal anesthesia for cesarean delivery with the least physician interference.


Eligibility criteria:
inclusion criteria: * parturients beyond 37 weeks gestation * asa і or іі exclusion criteria: * pregnancy-induced hypertension * chronic hypertension * multiple pregnancy * fetal compromise * diabetes mellitus * polyhydramnios * body weight \>100 kg * major systemic disease * anemia (hemoglobin concentration\<10 g/dl) * clotting diathesis

Keywords: spinal cesarean delivery phenylephrine hypotension